Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. The listed name for PGEN is Precigen, Inc. Common Stock.